Clinical Trial Update: Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating microwave ablation combined with tislelizumab and docetaxel for advanced non-small cell lung cancer after failure of fir…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Status: RECRUITING